

TENDER NO. BMSIC/DRUGS/24-03

Check list - I: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name :-Agron Remedles Pvt. Ltd.

Total Number of Pages Submitted in bid documents:- 1-132

Sl. No	SBD clause serial No	Description of the Clause/ Technical Eligibility Criteria as per SBD as mentioned in the Check List	Document/ fees submission status (Yes/ No)	Page number	Do the provided documents meet the eligibility criteria ? (Yes/ No)	Remarks
1	3. (a)	Tender Fee (Non-Refundable) of Rs 10,000/- + GST @18%, Total Rs 11,800 shall be submitted online (On E-Proc-2). This fee is payable only once for one tender irrespective of items contained therein.	Yes	17-18	Yes	-
2	3.(b)	EMD shall be submitted ONLY in form of Bank Guarantee (Offline mode), drawn in favor of Managing Director, Bihar Medical Services and Infrastructure Corporation Limited from any Scheduled/Nationalized bank payable at Patna, as mentioned in Clause 2, as per following table:- S.N. No. of drugs quoted EMD Amount 1 Upto 5 drugs Rs1,00,000/- (One Lakh only) 2 For 6 to 10 Drugs Rs 2,00,000/- (Two Lakh only) 3 For 11 to 15 Drugs Rs 3,00,000/- (Three Lakh only) 4 For 16 to 20 Drugs Rs 4,00,000/- (Four Lakh only) 5 More than 20 Drugs Rs 5,00,000/- (Five Lakh only)	Yes	21-24	Yes	As Per Bid Document clause 3(b) BG Submitted for EMD must be schedule/Nationalized Bank Payable at Patna But firm has not submitted the same.
3	3.(c)	Documentary evidence of the constitution of the company/firm/Proprietorship such as Memorandum and Articles of Association, Partnership Deed etc. should be submitted with details of the Name, Address, Telephone Number, Fax Number, e-mail address of the firm and of the Managing Director / Partners / Proprietor should be submitted.	Yes	06-10	Yes	-
4	3.(d)	The details of Bidder Name, Address, Telephone Number, Fax. Number, e-mail address of the bidder and of the Managing Director / Partners / Proprietor should be submitted in Annexure-V.	Yes	102	Yes	-
5	3.(e)	Power of Attorney or Resolution of the Board by which the authorized signatory has been authorized by the bidder firm to sign the documents should be submitted.	Yes	01	Yes	-
6	3.(l)	Copies of the Audited Balance Sheet and Profit and Loss statement showing details of their annual average turnover not less than 25 Crores (Twenty-Five) for any three of the last four consecutive financial years (Auditor/CA certificate of turnover will not be accepted). Self-attested copies are to be submitted.	Yes	48-55	Yes	-
7	3.(m)	Copy of Income Tax Return for any three of last four Consecutive Assessment years should be submitted (self-attested).	Yes	25-28	Yes	-
8	3.(p)	Copy of PAN Card of the bidder company should be submitted (self-attested).	Yes	37	Yes	-
9	3.(q)	Copy of certificate of valid GST registration of the bidder company should be submitted (self-attested).	Yes	38-40	Yes	-

Ankur
29/7/24

pu

TENDER NO. BMSIC/DRUGS/24-03

Check list - II: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name:- M/s Agron Remedies Pvt. Ltd. Total Number of Pages Submitted in bid documents:- 133

Sl. No	SBD Clause serial No	Description of the Clause/ Technical Eligibility Criteria as per SBD, as mentioned in Check List	Document/ fees submission status (Yes/ No)	Page Number as numbered by BMSICL	Do the provided documents meet the eligibility criteria ? (Yes/ No)	Remarks
1	3.(d)	The details of Bidder Name, Address, Telephone Number, Fax. Number, e-mail address of the bidder and of the Managing Director / Partners / Proprietor should be submitted in Annexure-V.	Yes	102	Yes	
2	3.(e)	Power of Attorney or Resolution of the Board by which the authorized signatory has been authorized by the bidder firm to sign the documents should be submitted.	Yes	1	Yes	
3	3.(f)	Minimum three years old valid Manufacturing License of the quoted product.	Yes	41-47 & 85-98	No	(I) For quoted product NIT sl. No. 5, 11, 19, 34, 36, 37, 38, 44, 45, & 49 product approval date is illegible in submitted documents (II) For quoted product NIT sl. No. 19, 24, 38 & 49 product approval is less than three years as per Annexur-III (III) For quoted product NIT sl. no. 37 product approval submitted for tablet instead of injection. (IV) For NIT sl. no. 34 product strength is not as per NIT.
4		Manufacturing License along with approved product list must be valid till the last date of the submission of tender.	Yes	41-47 & 85-98	No	
5		Market standing certificate & Manufacturing certificate issued by the Licensing Authority as a Manufacturer for each drug quoted for the last 3 years (Certificate should be enclosed with list of items) except for the drugs falling under the category of 'New Drug' as defined by CDSCO (Central Drugs Standard Control Organisation). If permission in Form 46 from DCGI has been obtained, then the 3 years Manufacturing & Market standing clause will be relaxed. The provisions of Rule 122 E of Drugs and Cosmetics Act rule 1945 shall be applicable. Explanation- In case of Importers Permission in Form 45 from DCGI is required as Per Drugs & Cosmetics Act 1940 & Rules 1945.	Yes	83-84	Yes	
6		For all regulated products, the bidder should have at least two years of manufacturing and marketing experience of the particular items as a manufacturer for each regulated product quoted in the tender. However, this would not apply to regulated products which have been licensed by DCGI less than two years ago. A certificate from DCG (I) shall be required for all new regulated products to this effect.	NA	NA	NA	

Amber
25/7/24Amita Bala
25/07/2024Jens
27/7/24BAM
27/07/24

7		FFS (Flow Fill & Seal Process) Technology will be accepted wherever applicable.	NA	NA	NA	
8		Valid Pollution Control Clearance Certificate in accordance with Water [Prevention and control of Pollution] Act, 1974 & Air [Prevention and control of Pollution] Act, 1981 and Hazardous Wastes (Management, Handling & Trans Boundary Movement) Rules 2008 (Self Attested Copy of Certificate to be enclosed) (as applicable).	No	No	No	Not submitted
9		Bidders shall submit self-attested copies of required manufacturing license and approved product list in support of above-mentioned condition and they are required to specify the quoted product in their approved product list by highlighting it.	Yes	41-47 & 85-98	No	(I) For quoted product NIT sl. No. 5, 11, 19, 34, 36, 37, 38, 44, 45, & 49 product approval date is illegible in submitted documents (II) For quoted product NIT sl. No. 19, 24, 38 & 49 product approval is less than three years as per Annexur-III (III) For quoted product NIT sl. no. 37 product approval submitted for tablet instead of injection. (IV) For NIT sl. no. 34 product strength is not as per NIT.
10	3.(g)	In case of Importer, the bidder (importer) firm must have minimum three yearsold valid import License of the quoted product. All Quoted products should be accompanied by their invoices, statement and import License showing that the quoted product is being imported and sold in India by the bidder (Importer) firm minimum for Last three years. Import license must be valid on the last date of submission of tender.	NA	NA	NA	
11	3.(h)	Bidder must have Market Standing Certificate (in India) of minimum three years issued by the concerned Licensing Authority from Drugs Control Department for the quoted product. Self-attested copies are to be submitted.	Yes	83-84	Yes	
12	3.(i)	Non-Conviction Certificate (NCC) issued by the concerned Licensing Authority from Drugs Control Administration of the state for last three years should be submitted (wherever applicable). It should be not more than one year old. Self-attested copies are to be submitted.	Yes	29-36	Yes	
13	3.(j)	WHO-GMP/GMP (Good Manufacturing Practice) as per revised Schedule- 'M'/COPP Certificate of the manufacturing unit issued by the Licensing Authority/Drugs Control Department, (wherever applicable). The GMP certificate must not be older than one year from the date of publication of tender. Self-attested copies are to be submitted. Explanation- Generally the GMP Certificate is issued for one-year validity. Hence the provision that it should not be older than one year from the date of publication of tender implies mutatis mutandisthat the GMP certificate should remain valid till the date of submission of tender.	Yes	14-15	Yes	
14	3.(k)	Maximum Production Capacity Certificate (Section wise) issued by concerned Licensing Authority from Drugs Control Department highlighting the quoted product section (wherever applicable). Self-attested copies are to be submitted. In case of Importer, an affidavit (with Stamp) sworn before first class magistrate/ Notary stating the batch production capacity of the firm and also that said production (Importing) capacity shall be adequate for requirement laid in NIT. Importer will have also to submit Invoices/evidence of import in items of said product with quantity details.	Yes	11-13	Yes	

Amr
25/7/24

Ality Bala
25/07/2024

25/7/24

22/07/24

15	3.(n)	The tenderer should give an affidavit (with stamp) sworn before first class magistrate / Notary stating that the firm & its quoted product is not black listed / Debarred currently (as on the date of submission of the tender) by Central Government / Central Government agencies/any state government or any of the state government agencies / or any Drug procurement agencies or by BMSICL as per Annexure-II .	Yes	4-5	Yes	
16	3. (o)	List of items quoted in prescribed format as per Annexure-III duly signed.	Yes	2-3	Yes	
17	5.(k)	An Affidavit (with stamp) regarding acceptance of tender conditions to be submitted by the bidding firm as per Annexure-IV .	Yes	56-57	Yes	
18	5.(l)	Filled check list as per given Annexure-VI to be submitted at the time of uploading the bid.	Yes	99-100	Yes	
19	7.(c)	Power of Attorney or Resolution of the Board by which the authorized signatory has been authorized by the bidder firm should sign the documents in cases where person other than the Managing Director/Managing Partner or sole Proprietor signs the document.	Yes	1	Yes	
20	10.(c)	If a particular document/Certificate to be uploaded as specified in bid, is not applicable for a bidder, the bidder shall attach a scanned copy of declaration in the letter head stating that the specific document is not applicable/exempted for the bidder in connection to this tender.	NA	NA	NA	
21	2(d) Explanation	The price quoted by the bidders must not exceed the ceiling price as fixed by NPPA (National Pharmaceutical Pricing Authority) as per the provision of "Drugs Price Control Order" (wherever applicable) and the quoted rate should be at least 20% less than its MRP. In extraordinary cases the Managing Director, BMSICL has discretion to take decision. Explanation- In order to ensure procurement of the tendered drugs at the most appropriate and competitive rate, the bidders are directed to quote their lowest price as compared to the Rate provided to their respective Distributors/ Dealers/Wholesalers/ Carrying and Forwarding Agents/Authorized depot sales point in the State of Bihar. A Notarized affidavit to this effect on a Rs 100/- Non-judicial Stamp Paper should be submitted with the Bid in the prescribed format as mentioned in Annexure-VIII .	Yes	107-108	Yes	

Anita
25/7/24

Ality Bala
25/07/2024

22/7/24

22/07/24

TENDER NO. BMSIC/DRUGS/24-03

Check list - III: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name:- M/s Agron Remedies Pvt. Ltd. Total Number of Pages Submitted in bid documents:- 133

Sheet to be used for verification of product approval and market standing

Sl. No	NIT Sl. No	Name of the Quoted Drug		Pharmacopoeial Specification/ Strength		Pack Size		Dosage Form		Approval Details			Last 3yrs market standing certificate/ New Drug
		As per NIT	As per Approval	As per NIT	As per Approval	As per NIT	As per Approval	As per NIT	As per Approval	Approval From	Approved Upto	Approved in Brand /Generic Name	
1	3	Amikacin	Amikacin Injection IP 500 mg	500 mg	Each 2ml contains: Amikacin sulphate IP Eq. to Amikacin 500 mg	2 ml Vial	Pack size not mentioned	Injection	Injection	07.11.2019	31.12.2026	Generic	Submitted (Page no. 84-85)
2	5	Amoxycillin + Potassium Clavunate	Amoxycillin & Potassium Clavunate Tablet IP	Amoxycillin 500 mg + Clavunic Acid 125 mg	Each film coated tablet contains: Amoxycillin sodium IP Eq. to Amoxycillin 500 mg Potassium Clavunate IP Eq. to Clavunate Acid 125 mg	10x10	Not mentioned	Tablet	Tablet	Approval date is illegible in submitted document & as per Annexure-III approval date is 04.04.2013	31.12.2026	Generic	Submitted (Page no. 84-85)
3	9	Cefixime	Cefixime Tablet IP 50 mg	50mg (DT)	Each uncoated dispersible tablet contains: Cefixime IP Eq. to anhydrous Cefixime 50 mg	10 x 10	Not mentioned	Dispersible Tablet	Dispersible Tablet	17.08.2013	31.12.2026	Generic	Submitted (Page no. 84-85)
4	11	Ceftriaxone	Ceftriaxone Injection IP 250 mg	250mg	Each vial contains: Sterile Ceftriaxone sodium IP Eq. to anhydrous Ceftriaxone 250 mg	Vial	Vial	Powder for Injection	Injection	Approval date is illegible in submitted document & as per Annexure-III approval date is 26.08.2019	31.12.2026	Generic	Submitted (Page no. 84-85)
5	19	Etophylline + Theophylline	Etophylline and Theophylline	169.4mg + 50.6mg per 2ml	Each 2 ml contains: Etophylline IP 169.4mg Theophylline anhydrous 50.6mg	2 ml Ampoule	Not mentioned	Injection	Injection	Approval date is illegible in submitted document & as per Annexure-III approval date is 29.12.2023 (Product approval is less than three years)	31.12.2026	Generic	Submitted (Page no. 84-85)

Amika
25/7/24Ailthy Bala
25/07/2024BMS
22/7/24BMS
22/07/24

6	24	Lactulose	Lactulose Solution USP (For Govt. supply only)	10 g/15 ml	Each 5 ml contains: Lactulose 3.325 gm (As Lactulose concentrate USP)	100 ml bottle	Not mentioned	Oral liquid	Injection	10.09.2021 (Product approval is less than three years)	31.12.2026	Generic	Submitted (Page no. 84-85)
7	29	Meropenem	Meropenem Injection IP 500 mg	500mg	Each vial contains; Sterile Meropenem IP Eq. to anhydrous Meropenem 500 mg	Vial	Vial	Powder for Injection	Injection	07.11.2019	31.12.2026	Generic	Submitted (Page no. 84-85)
8	34	Ondansetron	Ondansetron Injection IP 2mg/ml	2mg/ml	Each ml contains: Ondansetron hydrochloride IP Eq. to Ondansetron 4 mg (Product specification is not as per NIT)	2 ml Ampoule	Not mentioned	Injection	Injection	Product Approval date is illegible in submitted document & as per Annexure-III approval date is 07.11.2019	31.12.2026	Generic	Submitted (Page no. 84-85)
9	36	Paracetamol	Paracetamol Injection	150mg/ml	Each ml contains: Paracetamol IP 150 mg	2ml Ampoule	Not mentioned	Injection	Injection	Product Approval date is illegible in submitted document & as per Annexure-III approval date is 11.07.2018	31.12.2026	Generic	Submitted (Page no. 84-85)
10	37	Promethazine	Promethazine Tablet IP 25 mg (Not as per NIT)	25mg/ml	Each film coated tablet contains: Promethazine hydrochloride IP 25 mg (Not as per NIT)	1 ml Vial	Not mentioned	Injection	Tablet (Not as per NIT)	Not as per NIT	31.12.2026	Generic	Submitted (Page no. 84-85)
11	38	Sodium chloride (Normal Saline)	Sodium chloride Nasal Drop IP	0.9% w/v	Composition: Sodium chloride IP 0.9% w/v	As Licensed	Not mentioned	Nasal Drop	Nasal Drop	Product Approval date is illegible in submitted document & as per Annexure-III approval date is 31.04.2024 (Product approval is less than three years)	31.12.2026	Generic	Submitted (Page no. 84-85)

Anita
25/7/24

ality Bala
25/07/2024

25/7/24

BMM
22/07/24

12	44	Tranxamic acid	Tranexamic acid Injection IP	100mg/ml	Each ml contains: Tranexamic acid IP 100 mg	5ml Ampoule	Not mentioned	Injection	Injection	Product Approval date is illegible in submitted document & as per Annexure-III approval date is 07.11.2019	31.12.2026	Generic	Submitted (Page no. 84-85)
13	45	Trihexyphenidyl	Trihexyphenidyl Hydrochloride Tablet IP	2 mg	Each uncoated tablet contains: Trihexyphenidyl Hcl IP 2 mg	10 x 10	Not mentioned	Tablet	Tablet	Product Approval date is illegible in submitted document & as per Annexure-III approval date is 15.02.2020	31.12.2026	Generic	Submitted (Page no. 84-85)
14	49	Zinc Sulphate	Zinc Sulphate Dispersible Tablet IP 20 mg	20mg	Each uncoated dispersible tablet contains: Zinc sulphate monohydrate IP Eq. to Elemental Zinc 20 mg	14 tablets should be packed in Aluminium -PVC Blister 10 Strips/Box	Not mentioned	Dispersible Tablet	Dispersible Tablet	Product Approval date is illegible in submitted document & as per Annexure-III approval date is 19.12.2023 (Product approval date is less than 3 years)	31.12.2026	Generic	Submitted (Page no. 84-85)

Amte
25/7/24

Nity Bala
25/07/2024

Shiv
22/7/24

BAM
22/07/24

TENDER NO. BMSIC/DRUGS/24-03

Check list - IV: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name:- M/s Agron Remedies Pvt. Ltd. Total Number of Pages Submitted in bid documents:- 133

Sheet for verification of licence details

Sl. No.	NIT Sl. No	Name of the Drug as per NIT	Manufacturer		Importer		Validity		GMP/ WHO GMP/ COPP (Import)	
			Forms Number	Manufacturing license Number	Forms Number	Import license Number	From	To	From	To
1	3	Amikacin	28	2/SC/P of 1987	NA	NA	27.11.1987	31.12.2027	02.08.2021	01.08.2024
2	5	Amoxycillin + Potassium Clavunate	28	2/SC/P of 1987	NA	NA	27.11.1987	31.12.2027	02.08.2021	01.08.2024
3	9	Cefixime	25	25 of 1986	NA	NA	25.10.1986	31.12.2027	02.08.2021	01.08.2024
4	11	Ceftriaxone	28	2/SC/P of 1987	NA	NA	27.11.1987	31.12.2027	02.08.2021	01.08.2024
5	19	Etophylline + Theophylline	28	2/SC/P of 1987	NA	NA	27.11.1987	31.12.2027	02.08.2021	01.08.2024

Amrta
25/7/24Amita Bala
25/07/2024JNV
25/7/24Bh
25/07/24

6	24	Lactulose	25	25 of 1986	NA	NA	25.10.1986	31.12.2027	02.08.2021	01.08.2024
7	29	Meropenem	28	2/SC/P of 1987	NA	NA	27.11.1987	31.12.2027	02.08.2021	01.08.2024
8	34	Ondansetron	28	2/SC/P of 1987	NA	NA	27.11.1987	31.12.2027	02.08.2021	01.08.2024
9	36	Paracetamol	28	2/SC/P of 1987	NA	NA	27.11.1987	31.12.2027	02.08.2021	01.08.2024
10	37	Promethazine	25	25 of 1986	NA	NA	25.10.1986	31.12.2027	02.08.2021	01.08.2024
11	38	Sodium chloride (Normal Saline)	28	2/SC/P of 1987	NA	NA	27.11.1987	31.12.2027	02.08.2021	01.08.2024

Anu
25/7/24

Nity Bala
25/07/2024

22/7/24

22/07/24

12	44	Tranexamic acid	28	2/SC/P of 1987	NA	NA	27.11.1987	31.12.2027	02.08.2021	01.08.2024
13	45	Trihexyphenidyl	25	25 of 1986	NA	NA	25.10.1986	31.12.2027	02.08.2021	01.08.2024
14	49	Zinc Sulphate	25	25 of 1986	NA	NA	25.10.1986	31.12.2027	02.08.2021	01.08.2024
Note:- Assisted in technical evaluation in reference to letter no. BMSIC/40030/214-2024/3159 dt 10.07.2024 on the basis of documents provided by BMSICL as check list II, III & IV. Provided checklist compiled with due deligence and care.Inspite, some inadvertent discreprencies could have been crept in. Humble request to all concerned to bring to the notice in due time if any discreprencies are observed for rectification.										

Amu
25/7/24

Ality Bala
25/07/2024

25/7/24

Bm
22/07/24